In March 2019, the Secretary of State for Health and Social Care commissioned NHS England and NHS Improvement to review NHS systems and processes to identify and recommend any action necessary to address any barriers to clinically appropriate prescribing of cannabis-based products for medicinal use (CBPMs) on the NHS.
The findings and recommendations are available in the document ‘Barriers to accessing cannabis-based products for medicinal use on NHS prescription‘.
Following the Government’s announcement on 01 November 2018 that it would reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the rescheduling, which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.
Guidance has been issued for clinicians to advise on the process for prescribing a CBPM.
A letter was sent to Clinical Commissioning Groups to outline the prescription of THC:CBD spray (Sativex).
A set of clinical frequently asked questions (FAQs) is available to provide further support to prescribers.
Letter reminding clinical teams about the patient registry for those people prescribed licensed or unlicensed cannabis-based products for medicinal use (CBPMs).